Global Influenza Vaccines Market Outlook 2018-2028 - Visiongain Report

Monday, July 2, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, July 2, 2018 /PRNewswire/ --

Forecasts for Trivalent Influenza Vaccines (TIV) &

Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments for Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other

The latest report from business intelligence provider

visiongain offers comprehensive analysis of the global influenza vaccines market. Visiongain assesses that this market will generate revenues of $3.5 billion in 2018.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. Visiongain' s new study tells you and tells you NOW.

In this brand new 138-page report you find 63 in-depth tables, charts and graphs - all unavailable elsewhere.

The report provides clear detailed insight into the global Influenza market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope Visiongain's new investigation shows revenue predictions at overall world market, submarket, company, product and national level.

That study gives individual analysis for two influenza vaccine submarkets, which are further divided by vaccine technologies: • Trivalent Influenza Vaccines (TIV) • Quadrivalent Influenza Vaccines (QIV)

Our new analysis also shows you revenue predictions for the vaccines produced by these five market leaders: and their market share: • Sanofi Pasteur • GSK • Seqirus • AstraZeneca • Protein Science Corporation. • Others

From 2018, large pharmaceutical companies and other biopharma specialists can prosper in that market. See how, discovering organisations' potentials.

Our report analyses the vaccines in research and development and assess their prospects once they enter the market. The R&D pipeline discusses: • Seasonal Influenza vaccines in development • Universal Influenza vaccines in development

The report includes forecasts to 2028 and analysis of pipeline developments for the following specific vaccines: • Fluzone / VaxiGrip • Seqirus • Fluarix / FluLaval • FluMist / Fluenz • FluBlok • Other

The study shows you prospects for those drug sales in developed and developing regions. There see individual revenue forecasts to 2028 for 11 countries: • United StatesJapan • The EU 5 - Germany, France, United Kingdom, Italy and Spain. • Brazil, Russia, India and China

Who should read this report? • Anyone within the influenza vaccines value chain. • Pharmaceutical companies • Vaccine manufacturers • Healthcare biotech companies • Generics and biosimilar producers • Drug delivery companies and other technology providers • Contract/clinical research organisations (CROs) • Pharma contract manufacturers, • Pharma/healthcare wholesale and distribution companies • Medical device companies • Healthcare diagnostics companies • R&D specialists • Business development managers • Marketing managers • Technologists • Suppliers • Investors • Banks • Government agencies • Contractors

Visiongain's study is intended for anyone requiring commercial analyses for the influenza vaccines market and leading companies. You find data, trends and predictions.

Buy our report today Global Influenza Vaccines Market Outlook 2018-2028: Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments for Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other. Avoid missing out by staying informed - get our report now.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website : https://www.visiongain.com/report/global-influenza-vaccines-market-outlook-2018-2028

Advisory Committee for Immunization Practices Astellas Pharmaceuticals AstraZeneca Bharat Immunologicals and Biologicals Corporation Limited Binnopharm Bio Farma  bioCSL BioManguinhos/Oswaldo Cruz Foundation BiondVax BiondVax Bionor Biremx Brazilian Ministry of Health Butantan Institute Cabtacuzino Institute Center for Biologics Evaluation and Research Centers for Disease Control and Prevention (CDC) Centre for Disease Control and Prevention Chemo-Sero-Therapeutic Research Institute China National Biotech Group China's National Regulatory Authority Chinese Food and Drug Administration ClearPath CSL CureVac Daiichi Sankyo Developing Countries Vaccine Manufacturers Network (DCVMN) Dynavax Flanders Institute Food and Drug Administration (FDA) FORT Fresenius Pharmaceuticals Gamma Vaccines Gavi Alliance Glaxo Smith Klein GlaxoWellcome Global Influenza Programme  Governmental Pharmaceutical Organization (GPO) Green Cross Corporation Grippol Health Service Bureau, Japan Hualan Bio Immune Targeting Systems Indian Association of Paediatrics International Vaccine Access Center (IVAC)  Janssen Pharmaceuticals Jenner Institute, University of oxford Johnson & Johnson Krka Pharmaceuticals Medicago Medicare Medicines and Healthcare products Regulatory Agency (MHRA) MedImmune Merck Mitsubishi Tanabe Pharma  MSD Pharmaceuticals National Health Service, UK Netherlands Vaccine Institute Novartis Organisation for Economic Co-operation and Development Panacea Biotech Partnership for Influenza Vaccine Introduction Petrovax Pfizer Protein Science Corporation Razi Institute  Sanofi Pasteur Seqirus  Serum Institute of India (SLL) Servizio Sanitario Nationale Shionogi Pharmaceuticals Sinopharm Sistema Unico de Saude SmithKline Beecham Takeda Pharmaceuticals Terumo Pharmaceuticals The Ministry of Health, Labour and Welfare, Japan The Scripps Research Institute Torlak Institut Ultriks US Department of Health and Human Services Vacsera VaxInnate VaxInnate Corporation  WHO Strategic Advisory Group of Experts World Health Organization

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

SOURCE Visiongain



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store